HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1

This publication has 28 references indexed in Scilit:

• Mouse Development and Cell Proliferation in the Absence of D-Cyclins
  Cell, 2004
• Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II–Induced Cardiovascular Hypertrophy in Rats In Vivo
  Circulation Research, 2003
• Rho‐associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferation
  Developmental Dynamics, 2002
• Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
  Journal of Clinical Investigation, 2001
• Cyclin A/cdk2 Activation Is Involved in Hypoxia-Induced Apoptosis in Cardiomyocytes
  Circulation Research, 2001
• Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells
  Kidney International, 1999
• Angiotensin II and Serum Differentially Regulate Expression of Cyclins, Activity of Cyclin-Dependent Kinases, and Phosphorylation of Retinoblastoma Gene Product in Neonatal Cardiac Myocytes
  Circulation Research, 1997
• Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton
  Current Opinion in Cell Biology, 1997
• Mice Lacking p27 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors
  Cell, 1996
• Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers
  The Journal of Clinical Pharmacology, 1992